Datopotamab Deruxtecan, often abbreviated as DATO, represents the significant advancement regarding targeted cancer care. This new antibody-drug conjugate joins the monoclonal immunoglobulin specifically directed at HER-2 expressing cells with an potent chemotherapeutic payload, deruxtecan. The process of action entails the antibody's ability to co